Predicted to have protein heterodimerization activity and protein homodimerization activity. Involved in several processes, including cellular response to glucocorticoid stimulus; positive regulation of necrotic cell death; and positive regulation of transcription by RNA polymerase II. Localizes to cytoplasm and extracellular space. Used to study anti-basement membrane glomerulonephritis; congestive heart failure; myocarditis; pleurisy; and uveitis. Biomarker of several diseases, including brain ischemia; inflammatory bowel disease (multiple); lipoid nephrosis; lung disease (multiple); and periodontal disease (multiple). Human ortholog(s) of this gene implicated in Mycobacterium avium complex disease; autoimmune disease (multiple); bronchial disease (multiple); macular degeneration; and rhinitis (multiple). Orthologous to human IL17A (interleukin 17A); PARTICIPATES IN interleukin-23 signaling pathway; interleukin-27 signaling pathway; INTERACTS WITH 1-chloro-2,4-dinitrobenzene; 2,4,6-trinitrobenzenesulfonic acid; 7,12-dimethyltetraphene.
resveratrol inhibits the reaction [tetrandrine inhibits the reaction [COL2A1 protein results in increased expression of IL17A protein]], tetrandrine inhibits the reaction [COL2A1 protein results in increased expression of IL17A protein]
Estradiol inhibits the reaction [Halothane results in increased expression of IL17A protein], fulvestrant inhibits the reaction [Estradiol inhibits the reaction [Halothane results in increased expression of IL17A protein]]
2-methyl-2H-pyrazole-3-carboxylic acid 2-methyl-4-o-tolylazophenylamide inhibits the reaction [Tetrachlorodibenzodioxin results in increased secretion of IL17A protein] more ...
[Trinitrobenzenesulfonic Acid results in increased susceptibility to [Ionomycin co-treated with Tetradecanoylphorbol Acetate]] which results in increased expression of IL17A protein
Methylene Blue inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of IL17A protein], Sulfasalazine inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of IL17A protein]
Trinitrobenzenesulfonic Acid results in increased expression of IL17A mRNA, Trinitrobenzenesulfonic Acid results in increased expression of IL17A protein
[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of IL17A mRNA, rosemarinic acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of IL17A mRNA]
[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of IL17A mRNA, rosemarinic acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of IL17A mRNA]
Alloxan results in increased expression of and results in increased secretion of IL17A protein, platycodin D inhibits the reaction [Alloxan results in increased expression of and results in increased secretion of IL17A protein]
[deoxynivalenol results in increased susceptibility to Antigens] which results in increased expression of IL17A protein, [ochratoxin A results in increased susceptibility to Antigens] which results in increased expression of IL17A protein
[Arsenic results in increased abundance of Cacodylic Acid] which affects the expression of IL17A mRNA, Arsenic results in decreased secretion of and results in decreased expression of IL17A protein
[Arsenic results in increased abundance of Cacodylic Acid] which affects the expression of IL17A mRNA, Arsenic results in decreased secretion of and results in decreased expression of IL17A protein
2-methyl-2H-pyrazole-3-carboxylic acid 2-methyl-4-o-tolylazophenylamide inhibits the reaction [bisphenol A affects the secretion of IL17A protein], Cholecalciferol inhibits the reaction [bisphenol A results in increased secretion of IL17A protein]
2-methyl-2H-pyrazole-3-carboxylic acid 2-methyl-4-o-tolylazophenylamide inhibits the reaction [bisphenol F results in increased secretion of IL17A protein]
[Air Pollutants results in increased abundance of [Carbon Monoxide co-treated with Nitrogen Oxides co-treated with Sulfur Dioxide]] which results in increased expression of IL17A protein
[PTGS2 gene mutant form results in increased susceptibility to [Nanotubes, Carbon co-treated with OVAL protein]] which results in increased expression of IL17A mRNA
[celastrol co-treated with coomassie Brilliant Blue] inhibits the reaction [Acetaminophen results in increased expression of IL17A protein], celastrol inhibits the reaction [Dextran Sulfate results in increased expression of IL17A protein]
[Dietary Fats co-treated with Choline deficiency] results in increased expression of IL17A protein, PANX1 gene mutant form inhibits the reaction [[Dietary Fats co-treated with Choline deficiency] results in increased expression of IL17A protein]
corosolic acid analog inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of IL17A mRNA], corosolic acid inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of IL17A mRNA]
[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of IL17A mRNA, rosemarinic acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of IL17A mRNA]
[cyanidin inhibits the reaction [[IL17A protein co-treated with Freund's Adjuvant] results in increased expression of and results in increased phosphorylation of STAT3 protein]] which results in increased expression of PIAS3 protein more ...
Fungal Polysaccharides inhibits the reaction [Cyclophosphamide results in decreased expression of IL17A protein], Levamisole inhibits the reaction [Cyclophosphamide results in decreased expression of IL17A protein]
[lead chloride results in increased abundance of Lead] promotes the reaction [decabromobiphenyl ether results in increased expression of IL17A protein], decabromobiphenyl ether promotes the reaction [[lead chloride results in increased abundance of Lead] which results in increased expression of IL17A protein]
[deoxynivalenol results in increased susceptibility to Antigens] which results in increased expression of IL17A protein, Celecoxib inhibits the reaction [deoxynivalenol results in increased expression of IL17A protein]
[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of IL17A mRNA, rosemarinic acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of IL17A mRNA]
2-1'H-indole-3'-carbonylthiazole-4-carboxylic acid methyl ester inhibits the reaction [Dextran Sulfate results in increased expression of IL17A protein] more ...
[Iodine co-treated with Dibutyl Phthalate] results in increased expression of IL17A protein, pyrazolanthrone inhibits the reaction [[Iodine co-treated with Dibutyl Phthalate] results in increased expression of IL17A protein]
[Iodine co-treated with Dibutyl Phthalate] results in increased expression of IL17A protein, pyrazolanthrone inhibits the reaction [[Iodine co-treated with Dibutyl Phthalate] results in increased expression of IL17A protein]
ferulic acid inhibits the reaction [Imiquimod results in increased expression of IL17A mRNA], ferulic acid inhibits the reaction [Imiquimod results in increased expression of IL17A protein]
[IL17A protein co-treated with Floxacillin] results in increased expression of MPO protein, IL17A protein promotes the reaction [Floxacillin results in increased expression of GPT protein]
[morin co-treated with Indomethacin] inhibits the reaction [Freund's Adjuvant results in increased expression of IL17A mRNA], Indomethacin inhibits the reaction [Freund's Adjuvant results in increased expression of IL17A mRNA]
[Trinitrobenzenesulfonic Acid results in increased susceptibility to [Ionomycin co-treated with Tetradecanoylphorbol Acetate]] which results in increased expression of IL17A protein
[lead chloride results in increased abundance of Lead] promotes the reaction [decabromobiphenyl ether results in increased expression of IL17A protein] more ...
[lead chloride results in increased abundance of Lead] promotes the reaction [decabromobiphenyl ether results in increased expression of IL17A protein] more ...
[lead chloride results in increased abundance of Lead] promotes the reaction [decabromobiphenyl ether results in increased expression of IL17A protein] more ...
Methotrexate inhibits the reaction [Freund's Adjuvant results in increased expression of IL17A mRNA], Methotrexate inhibits the reaction [Freund's Adjuvant results in increased expression of IL17A protein]
[morin co-treated with Indomethacin] inhibits the reaction [Freund's Adjuvant results in increased expression of IL17A mRNA], morin inhibits the reaction [Freund's Adjuvant results in increased expression of IL17A mRNA]
Acetylcysteine inhibits the reaction [Azoxymethane results in increased expression of IL17A protein], Acetylcysteine inhibits the reaction [Trichloroethylene results in increased expression of IL17A mRNA]
[Trinitrobenzenesulfonic Acid results in increased susceptibility to [Ionomycin co-treated with Tetradecanoylphorbol Acetate]] which results in increased expression of IL17A protein
platycodin D inhibits the reaction [[IL6 protein co-treated with TGFB1 protein] results in increased expression of and results in increased secretion of IL17A protein], platycodin D inhibits the reaction [Alloxan results in increased expression of and results in increased secretion of IL17A protein]
Mifepristone inhibits the reaction [Progesterone promotes the reaction [Halothane results in increased expression of IL17A protein]], Progesterone promotes the reaction [Halothane results in increased expression of IL17A protein]
stannous mesoporphyrin inhibits the reaction [4-4-3-adamantan-1-ylureidocyclohexyloxybenzoic acid inhibits the reaction [Streptozocin results in increased expression of IL17A protein]]
[Air Pollutants results in increased abundance of [Carbon Monoxide co-treated with Nitrogen Oxides co-treated with Sulfur Dioxide]] which results in increased expression of IL17A protein
Carbon Tetrachloride results in increased secretion of and results in decreased expression of IL17A protein, INCB018424 inhibits the reaction [Carbon Tetrachloride results in increased secretion of and results in decreased expression of IL17A protein]
tofacitinib inhibits the reaction [enterotoxin A, Staphylococcal results in increased expression of and results in increased secretion of IL17A protein]
[Trichloroethylene co-treated with Dietary Fats] results in increased expression of IL17A mRNA, Acetylcysteine inhibits the reaction [Trichloroethylene results in increased expression of IL17A mRNA]
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
